Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
27.2M
-
Number of holders
-
41
-
Total 13F shares, excl. options
-
5.22M
-
Shares change
-
-13.7M
-
Total reported value, excl. options
-
$1.2M
-
Value change
-
-$30M
-
Put/Call ratio
-
6.91
-
Number of buys
-
16
-
Number of sells
-
-36
-
Price
-
$0.23
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) as of Q4 2024
76 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share as of Q4 2024.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) has 41 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.22M shares
of 27.2M outstanding shares and own 19.18% of the company stock.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (2.75M shares), BlackRock, Inc. (277K shares), VANGUARD GROUP INC (268K shares), Omega Fund Management, LLC (251K shares), ACADIAN ASSET MANAGEMENT LLC (249K shares), GEODE CAPITAL MANAGEMENT, LLC (196K shares), Affinity Asset Advisors, LLC (150K shares), CITIGROUP INC (139K shares), Qube Research & Technologies Ltd (122K shares), and TWO SIGMA SECURITIES, LLC (108K shares).
This table shows the top 41 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.